CytoSorbents Corporation announced a combined $6.25 million financing and restructuring of its credit facility on November 19, 2026. The company entered into securities purchase agreements with institutional investors, directors, and executive officers for the sale of common stock and pre-funded warrants.

The offering consists of 556,681 shares of common stock sold at $4.94 per share, 96,527 shares issued to insiders at $5.18 per share, and 151,822 pre-funded warrants to purchase common stock at $4.939 per warrant. The offering is expected to generate approximately $4.0 million in gross proceeds before expenses, with an estimated net proceeds of $3.5 million. H.C. Wainwright & Co. serves as the exclusive placement agent, and WBB Securities acts as financial advisor.

Concurrently, the company entered into the Third Amendment to its Loan and Security Agreement with Avenue Capital Group. The amendment reduces the outstanding principal debt by approximately $5.25 million, bringing the remaining balance to $12.25 million. This reduction includes a $3.0 million cash repayment and the issuance of 455,465 shares of common stock to Avenue Venture Opportunities Fund, L.P., valued at the offering price of $4.94 per share.

Under the amended terms, the maturity date of the loan is extended to July 1, 2028, and the interest-only period is extended through March 31, 2028. The company also agreed to new conversion rights for Avenue, allowing the lender to convert up to $6.125 million of principal into common stock at prices ranging from $6.916 to $8.645 per share, subject to FDA marketing approval or specific dates.